Glo-BNHL
Research type
Research Study
Full title
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
IRAS ID
1004701
Contact name
Gladstone Burke
Contact email
Sponsor organisation
University of Birmingham
Research summary
The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL). B-NHL is a type of cancer that develops inside or outside of lymph nodes (glands) and organs such as the liver or spleen. Examples of B-NHL are Burkitt Lymphoma and Diffuse Large B Cell Lymphoma, which may be other names used to describe this type of cancer. It is very difficult to cure relapsed or refractory B-NHL. The medicines used now are very powerful with many side effects and only cure around 30 in every 100 children treated. It is very important that we quickly find better medicines for these children and young people.
The Glo-BNHL trial will include three groups of children and young people, each given a new medicine (either alone or with chemotherapy). We are looking to make sure the new medicines are safe and that they work to treat the cancer. If the medicine in one group does not work for a child in the trial, then they may be able to join a different group to have another new medicine.
Experts from around the world will carefully pick the medicines most likely to be helpful to be part of the trial. If one of the new medicines seems not to be working as well as hoped then we will take it out of the trial as soon as we can. This will let other new medicines be added to be tested. If a medicine does seem to be working well, then it will continue in the trial to make sure it really is the most useful medicine we have.
Children from around the world will be invited to take part in the trial. We will then check on them for at least two years after they finish the trial treatment to look for possible side effects of the new medicine.
REC name
London - City & East Research Ethics Committee
REC reference
23/LO/0730
Date of REC Opinion
6 Oct 2023
REC opinion
Further Information Favourable Opinion